AR092955A1 - Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona - Google Patents

Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona

Info

Publication number
AR092955A1
AR092955A1 ARP130103661A ARP130103661A AR092955A1 AR 092955 A1 AR092955 A1 AR 092955A1 AR P130103661 A ARP130103661 A AR P130103661A AR P130103661 A ARP130103661 A AR P130103661A AR 092955 A1 AR092955 A1 AR 092955A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
group
twice
membered
Prior art date
Application number
ARP130103661A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR092955A1 publication Critical patent/AR092955A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La presente se refiere a derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona de fórmula (1). Composiciones farmacéuticas que contienen uno o más compuestos de fórmula (1), y a su uso como productos farmacéuticos, especialmente a su uso como antagonistas de los receptores de orexina. Reivindicación 1: Un compuesto de fórmula (1) en la cual el átomo de carbono en posición 2 del anillo de pirrolidina está en configuración (S) absoluta; R representa hidrógeno o metilo; el anillo A³ representa un anillo heteroarileno de 5 miembros sustituido dos veces en posición meta que contiene uno, dos o tres heteroátomos; donde por lo menos uno de dichos heteroátomos es nitrógeno, y el resto es/ son seleccionado/s independientemente entre oxígeno, azufre y nitrógeno; el anillo A² representa arilo o heteroarilo de 5 a 10 miembros; donde dicho arilo o heteroarilo de 5 a 10 miembros es independientemente no sustituido, o sustituido una, dos o tres veces; donde los sustituyentes son seleccionados independientemente del grupo que consiste en alquilo C₁₋₄, alcoxi C₁₋₄, cicloalquilo C₃₋₆, halógeno, ciano, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃, hidroxi, alcoxi C₁₋₄-alquilo C₁₋₃, hidroxi-alquilo C₁₋₃, -CO-alquilo C₁₋₄, y cicloalquil C₃₋₆-oxi-; o el anillo A² representa un grupo 2,3-dihidro-benzo[1,4]dioxinilo, un grupo 2,3-dihidro-benzofuranilo, o un grupo benzo[1,3]dioxolilo opcionalmente sustituido dos veces con flúor; y el anillo A¹ representa fenilo o heteroarilo de 5 ó 6 miembros, donde dicho fenilo o heteroarilo de 5 ó 6 miembros está independientemente sustituido una, dos o tres veces; donde uno de dichos sustituyentes está unido en posición orto al punto de unión de A¹ al resto de la molécula; donde dicho sustituyente es fenilo o heteroarilo de 5 ó 6 miembros; donde dicho sustituyente fenilo o heteroarilo de 5 ó 6 miembros está independientemente sin sustituir, sustituido una, dos o tres veces, donde los sustituyentes son seleccionados independientemente del grupo que consiste en alquilo C₁₋₄, alcoxi C₁₋₄, halógeno, ciano, fluoroalquilo C₁₋₃, y fluoroalcoxi C₁₋₃; y el otro de dichos sustituyentes, si está presente, es/son seleccionado/s independientemente del grupo que consiste en alquilo C₁₋₄, alcoxi C₁₋₄, halógeno, ciano, fluoroalquilo C₁₋₃, y fluoroalcoxi C₁₋₃; siempre que el anillo A¹ no sea isoxazol-4-ilo, sustituido en posición 5 con alquilo C₁₋₄, unido al resto de la molécula en posición 4, y que porta dicho sustituyente orto adicional en posición 3; con la excepción del compuesto (1,1-bifenil)-2-il-{(S)-2-[3-(3-piridinil)-1H-1,2,4-triazol-5-il]-1-pirrolidinil}-metanona; o su sal farmacéuticamente aceptable.
ARP130103661A 2012-10-10 2013-10-09 Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona AR092955A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188019 2012-10-10
EP13157809 2013-03-05

Publications (1)

Publication Number Publication Date
AR092955A1 true AR092955A1 (es) 2015-05-06

Family

ID=49765598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103661A AR092955A1 (es) 2012-10-10 2013-10-09 Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona

Country Status (16)

Country Link
US (1) US9493446B2 (es)
EP (1) EP2906553B1 (es)
JP (1) JP6244365B2 (es)
KR (1) KR102151288B1 (es)
CN (1) CN104703980B (es)
AR (1) AR092955A1 (es)
AU (1) AU2013328301A1 (es)
BR (1) BR112015007516A2 (es)
CA (1) CA2885180C (es)
EA (1) EA201500399A1 (es)
IL (1) IL238052A0 (es)
MX (1) MX2015004638A (es)
PH (1) PH12015500627A1 (es)
SG (1) SG11201502493XA (es)
TW (1) TW201414727A (es)
WO (1) WO2014057435A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510481B (zh) 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
SG11201804223TA (en) 2015-11-23 2018-06-28 Sunshine Lake Pharma Co Ltd OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
CN106986859B (zh) * 2016-01-20 2020-02-11 广东东阳光药业有限公司 吲哚衍生物及其用途
JP7012703B2 (ja) * 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
CN108794454B (zh) * 2017-04-27 2023-08-15 广东东阳光药业股份有限公司 一种咪唑环化合物的制备方法
RS62357B1 (sr) * 2017-05-03 2021-10-29 Idorsia Pharmaceuticals Ltd Dobijanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline
WO2019018795A1 (en) * 2017-07-20 2019-01-24 Yumanity Therapeutics COMPOUNDS AND USES THEREOF
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
CN111655260A (zh) 2017-10-26 2020-09-11 南方研究院 作为TGF-β抑制剂的噁二唑和噻二唑
US10919885B2 (en) 2018-04-25 2021-02-16 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11897850B1 (en) 2023-10-11 2024-02-13 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
DE60110066T2 (de) 2000-06-16 2006-02-02 Smithkline Beecham P.L.C., Brentford Piperidine zur verwendung als orexinrezeptorantagonisten
DE60108420T2 (de) 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
EP1435955A2 (en) 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
CN100448874C (zh) 2001-05-05 2009-01-07 史密斯克莱·比奇曼公司 N-芳酰基环胺
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
HUP0400326A2 (hu) 2001-06-28 2004-09-28 Smithkline Beecham P.L.C. Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10240818A1 (de) * 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
US20060040937A1 (en) 2002-09-18 2006-02-23 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AR044586A1 (es) 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US7269781B2 (en) 2004-06-25 2007-09-11 Hewlett-Packard Development Company, L.P. Discrete universal denoising with reliability information
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
KR101065239B1 (ko) 2006-03-15 2011-09-16 액테리온 파마슈티칼 리미티드 기억 기능을 증진하는 테트라히드로이소퀴놀린 유도체
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
ES2360376T3 (es) 2006-08-15 2011-06-03 Actelion Pharmaceuticals Ltd. Compuestos de azetidina como antagonistas del receptor de orexina.
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
DE602007012142D1 (en) 2006-12-01 2011-03-03 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
JP2010526869A (ja) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9150556B2 (en) 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
JP2010528007A (ja) 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
EP2155738B1 (en) 2007-06-01 2011-08-03 F. Hoffmann-La Roche AG Piperidine-amide derivatives
KR20100041805A (ko) 2007-07-03 2010-04-22 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.3.0]옥탄 화합물
EP2176258A1 (en) 2007-07-03 2010-04-21 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
US7751938B2 (en) 2007-07-05 2010-07-06 Panasonic Corporation Robot arm control device and control method, robot, and control program
TW200904799A (en) 2007-07-27 2009-02-01 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
JP2010534647A (ja) 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド ２−アザ−ビシクロ［３．３．０］オクタン誘導体
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
MX2010006241A (es) 2007-12-18 2010-06-30 Actelion Pharmaceuticals Ltd Derivados de aminotriazol como agonistas de alx.
CA2713184A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
US20110212968A1 (en) 2008-10-14 2011-09-01 Hamed Aissaoui Phenethylamide derivatives and their heterocyclic analogues
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
JP2012509911A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
AU2009324238A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
TW201033190A (en) 2008-12-02 2010-09-16 Glaxo Group Ltd Novel compounds
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
WO2010114978A1 (en) 2009-04-03 2010-10-07 Merck Sharp & Dohme Corp. Renin inhibitors
CA2759160A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
KR101444559B1 (ko) 2009-06-09 2014-09-26 액테리온 파마슈티칼 리미티드 불화 아미노트리아졸 유도체
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
DK3093291T3 (da) 2009-10-23 2019-07-29 Janssen Pharmaceutica Nv Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2012039717A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
TWI510481B (zh) 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists

Also Published As

Publication number Publication date
EP2906553A1 (en) 2015-08-19
CN104703980A (zh) 2015-06-10
BR112015007516A2 (pt) 2017-07-04
CA2885180A1 (en) 2014-04-17
JP6244365B2 (ja) 2017-12-06
EA201500399A1 (ru) 2015-09-30
US20150252032A1 (en) 2015-09-10
IL238052A0 (en) 2015-05-31
PH12015500627A1 (en) 2015-05-11
KR102151288B1 (ko) 2020-09-03
SG11201502493XA (en) 2015-04-29
WO2014057435A1 (en) 2014-04-17
US9493446B2 (en) 2016-11-15
CN104703980B (zh) 2017-09-22
TW201414727A (zh) 2014-04-16
AU2013328301A1 (en) 2015-05-28
KR20150064753A (ko) 2015-06-11
MX2015004638A (es) 2015-07-14
CA2885180C (en) 2021-03-02
AU2013328301A8 (en) 2015-06-11
JP2015533157A (ja) 2015-11-19
EP2906553B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
PE20130155A1 (es) Derivados de ariletinilo
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR091257A1 (es) Derivados de bencimidazol-prolina
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
AR088235A1 (es) Derivados de pirazoloquinolina
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR077055A1 (es) Derivados de benzimidazol como moduladores del canal trpm8
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
EA201790661A3 (ru) Ингибиторы вируса гепатита c
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
PE20090511A1 (es) Imidazopiridinonas
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
MY184433A (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة

Legal Events

Date Code Title Description
FB Suspension of granting procedure